Pharmacokinetics and disposition of CS-023 (RO4908463), a novel parenteral carbapenem, in animals

Antimicrobial Agents and Chemotherapy

Volumn 51, Issue 1, 2007, Pages 257-263

  Shibayama, Takahiro ^a   Matsushita, Yoko ^a   Kawai, Kenji ^a   Hirota, Takashi ^a   Ikeda, Toshihiko ^a   Kuwahara, Shogo ^b  

^a DAIICHI SANKYO CO   (Japan)

^b TOHO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BETA LACTAM; CARBAPENEM DERIVATIVE; CARBON 14; CS 023; DEHYDROPEPTIDASE I; PARACETAMOL; PEPTIDASE; R 131624; RO 4908463; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; AUTORADIOGRAPHY; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; DOG; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG URINE LEVEL; ISOTOPE LABELING; KIDNEY; LUNG; MALE; MONKEY; NONHUMAN; PRIORITY JOURNAL; RAT; SINGLE DRUG DOSE; SPECIES COMPARISON; TESTIS;

ANIMALS; CARBAPENEMS; CHROMATOGRAPHY, THIN LAYER; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; FECES; HAPLORHINI; MALE; MOLECULAR STRUCTURE; RADIOISOTOPES; RATS; RATS, SPRAGUE-DAWLEY; TISSUE DISTRIBUTION;

EID: 33845997465     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.00459-06     Document Type: Article

References (18)

1. Burman, L. A., I. Nilsson-Ehle, M. Hutchison, S. J. Haworth, and S. R. Norrby. 1991. Pharmacokinetics of meropenem and its metabolite ICI 213,689 in healthy subjects with known renal metabolism of imipenem. J. Antimicrob. Chemother. 27:219-224.
2. Davies, B., and T. Morris. 1993. Physiological parameters in laboratory animals and humans. Pharm. Res. 10:1093-1095.
3. Fukasawa, M., Y. Sumita, E. T. Harabe, T. Tanio, H. Nouda, T. Kohzuki, T. Okuda, H. Matsumura, and M. Sunagawa. 1992. Stability of meropenem and effect of 1 beta-methyl substitution on its stability in the presence of renal dehydropeptidase I. Antimicrob. Agents Chemother. 36:1577-1579.
4. Goa, K. L., and S. Noble. 2003. Panipenem/betamipron. Drugs 63:913-925. 5. Kahan, F. M., H. Kropp, J. G. Sundelof, and J. Birnbaum. 1983. Thienamycin: development of imipenem-cilastatin. J. Antimicrob. Chemother. 12(Suppl. D):1-35.
5. Kawamoto, I., Y. Shimoji, O. Kanno, K. Kojima, K. Ishikawa, E. Matsuyama, Y. Ashida, T. Shibayama, T. Fukuoka, and S. Ohya. 2003. Synthesis and structure-activity relationships of novel parenteral carbapenems, CS-023 (R-115685) and related compounds containing an amidine moiety. J. Antibiot. 56:565-579.
6. Koga, T., T. Abe, H. Inoue, T. Takenouchi, A. Kitayama, T. Yoshida, N. Masuda, C. Sugihara, M. Kakuta, M. Nakagawa, T. Shibayama, Y. Matsushita, T. Hirota, S. Ohya, Y. Utsui, T. Fukuoka, and S. Kuwahara. 2005. In vitro and in vivo antibacterial activities of CS-023 (RO4908463), a novel parenteral carbapenem. Antimicrob. Agents Chemother. 49:3239-3250.
7. Kropp, H., J. G. Sundelof, R. Hajdu, and F. M. Kahan. 1982. Metabolism of thienamycin and related carbapenem antibiotics by the renal dipeptidase, dehydropeptidase-I. Antimicrob. Agents Chemother. 22:62-70.
8. Masuda, N., S. Ohya, T. Takenouchi, M. Kakuta, C. Ishii, E. Sakagawa, T. Abe, and S. Kuwahara. 2000. R-115685, a novel parenteral carbapenem: mode of action and resistance mechanisms, abstr. F-1231. In Abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
9. Nix, D. E., A. K. Majumdar, and M. J. DiNubile. 2004. Pharmacokinetics and pharmacodynamics of ertapenem: an overview for clinicians. J. Antimicrob. Chemother. 53:ii23-ii28.
10. Pacifici, G. M., and A. Viani. 1992. Methods of determining plasma and tissue binding of drugs. Pharmacokinetics consequences. Clin. Pharmacokinet. 23:449-468.
11. Perry, C. M., and T. Ibbotson. 2002. Biapenem. Drugs 62:2221-2234.
12. Rennecke, J. T., T. Hirota, T. Shibayama, Y. Matsushita, S. Kuwahara, K. Puchler, A. Ruhland, and B. Drewelow. 2002. Safety, tolerability, and pharmacokinetics (PK) of CS-023, a new parenteral carbapenem, in healthy male volunteers, abstr. F-327. In Abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology. Washington, D.C.
13. 14. Shentag, J. J. 1990. The significance of the relationship between tissue:serum ratios, tissue concentrations and the location of microorganisms. Res. Clin. Forums 12:23-27.
14. Sundelof, J. G., R. Hajdu, C. J. Gill, R. Thompson, H. Rosen, and H. Kropp. 1997. Pharmacokinetics of L-749,345, a long-acting carbapenem antibiotic, in primates. Antimicrob. Agents Chemother. 41:1743-1748.
15. Takahagi, H., T. Hirota, Y. Matsushita, S. Muramatsu, M. Tanaka, and E. Matsuo. 1991. In vitro dehydropeptidase-I activity and its hydrolytic activity of panipenem in several tissues in animal species and their influence on the disposition of panipenem in vivo. Chemotherapy (Tokyo) 39(Suppl. 3):236-241.
16. Thomson, K. S., and E. S. Moland. 2004. CS-023 (R-115685), a novel carbapenem with enhanced in vitro activity against oxacillin-resistant staphylococci and Pseudomonas aeruginosa. J. Antimicrob. Chemother. 54:557-562.
17. Wiseman, L. R., A. J. Wagstaff, R. N. Brogden, and H. M. Bryson. 1995. Meropenem. A review of its antibacterial activity, pharmacokinetic properties and clinical efficacy. Drugs 50:73-101.
18. Yamamoto, C., T. Takahashi, K. Kinoshita, and T. Fujita. 1982. The metabolic fate of 4-amino-2-(4-butanoylhexahydro-1H-1,4-diazepin-1-yl)-6,7- dimethoxy-quinazoline HCl. Xenobiotica 12:549-559.